Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease

Rezazadeh, Farzaneh; Ramos, Nicholas; Saliganan, Allen-Dexter; Al-Hallak, Najeeb; Chen, Kang; Mohamad, Bashar; Wiesend, Wendy N.; Viola-Villegas, Nerissa

doi:10.2967/jnumed.123.265649

Cited by 4 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of an immuno-PET for targeting IL-12/23p40 was investigated for imaging inflammation in a DSS-induced colitis mouse model. In a study by Rezazadeh et al (34), an anti-IL-12/23p40 immuno-PET agent was developed by radiolabeling an antimouse IL-12/23p40 antibody with the PET radionuclide 89 Zr using DFO as the chelator. The tracer clearly delineated intestinal inflammation in the colon, cecum, and small intestine of DSS mice at 24 and 48 h after injection (Fig.…”

Section: Inflammatory Cytokinesmentioning

confidence: 99%

Imaging Agents for PET of Inflammatory Bowel Disease: A Review

Rezazadeh,

Kilcline,

Viola

2023

J Nucl Med

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which encompasses ulcerative colitis and Crohn disease, is a chronic inflammatory disorder resulting from an aberrant immune response, though its exact cause is unknown. The current mainstay standard of care for the diagnosis and surveillance of IBD is endoscopy. However, this methodology is invasive and images only superficial tissue structures, revealing very little about the molecular drivers of inflammation. Accordingly, there is an unmet need for noninvasive imaging tools that provide reliable and quantitative visualization of intestinal inflammation with high spatial and molecular specificity. In recent years, several PET agents for imaging IBD have been reported. Such agents allow noninvasive visualization and quantification of dynamic molecular inflammatory processes in vivo. This review focuses on recent advancements in the development of PET tracers for imaging biomarkers of interest in IBD pathogenesis, such as cell-surface molecules that are overexpressed on immune cells and cytokines that perpetuate inflammatory signaling.

show abstract

Section: Inflammatory Cytokinesmentioning

confidence: 99%

Imaging Agents for PET of Inflammatory Bowel Disease: A Review

Rezazadeh,

Kilcline,

Viola

2023

J Nucl Med

Self Cite

View full text Add to dashboard Cite

show abstract

Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments

Wangchuk,

Yeshi,

Loukas

2024

Trends in Pharmacological Sciences

View full text Add to dashboard Cite

Key Interleukins in Inflammatory Bowel Disease—A Review of Recent Studies

Aebisher,

Bartusik-Aebisher,

Przygórzewska

et al. 2024

IJMS

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an immune disorder of the gastrointestinal tract with a complex aetiopathogenesis, whose development is influenced by many factors. The prevalence of IBD is increasing worldwide, in both industrialized and developing countries, making IBD a global health problem that seriously affects quality of life. In 2019, there were approximately 4.9 million cases of IBD worldwide. Such a large number of patients entails significant healthcare costs. In the treatment of patients with IBD, the current therapeutic target is mucosal healing, as intestinal inflammation often persists despite resolution of abdominal symptoms. Treatment strategies include amino salicylates, corticosteroids, immunosuppressants, and biologic therapies that focus on reducing intestinal mucosal inflammation, inducing and prolonging disease remission, and treating complications. The American College of Gastroenterology (ACG) guidelines also indicate that nutritional therapies may be considered in addition to other therapies. However, current therapeutic approaches are not fully effective and are associated with various limitations, such as drug resistance, variable efficacy, and side effects. As the chronic inflammation that accompanies IBD is characterized by infiltration of a variety of immune cells and increased expression of a number of pro-inflammatory cytokines, including IL-6, TNF-α, IL-12, IL-23 and IFN-γ, new therapeutic approaches are mainly targeting immune pathways. Interleukins are one of the molecular targets in IBD therapy. Interleukins and related cytokines serve as a means of communication for innate and adaptive immune cells, as well as nonimmune cells and tissues. These cytokines play an important role in the pathogenesis and course of IBD, making them promising targets for current and future therapies. In our work, we review scientific studies published between January 2022 and November 2024 describing the most important interleukins involved in the pathogenesis of IBD. Some of the papers present new data on the precise role that individual interleukins play in IBD. New clinical data have also been provided, particularly on blocking interleukin 23 and interleukin 1beta. In addition, several new approaches to the use of different interleukins in the treatment of IBD have been described in recent years.

show abstract

Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease

Cited by 4 publications

References 45 publications

Imaging Agents for PET of Inflammatory Bowel Disease: A Review

Imaging Agents for PET of Inflammatory Bowel Disease: A Review

Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments

Key Interleukins in Inflammatory Bowel Disease—A Review of Recent Studies

Contact Info

Product

Resources

About